When comparing KIR3DL2+ and KIR3DL2− populations of CD4+ T cells, a decrease in KIR3DL2 expressing T cells is associated with the response to therapy when increased KIR3DL2− CD4+ T cells are observed, highlighting the usefulness of this marker for the follow-up of SS patients (17). Here, KIR3DL2 is linked to synovial sarcoma.